NewAms­ter­dam hits pri­ma­ry end­point in lat­est Phase 3 tri­al of CETP in­hibitor

NewAms­ter­dam Phar­ma’s car­dio drug suc­ceed­ed in a third read­out this year, show­ing that obice­trapib could low­er a type of lipopro­tein that car­ries cho­les­terol in the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER